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RANKL–RANK pathwayThe maintenance of bone homeostasis is largely dependent upon cellular communication between osteoclasts
and osteoblasts. Microvesicles (MVs) have received a good deal of attention and are increasingly considered as
mediators of intercellular communication due to their capacity to merge with and transfer a repertoire of bioac-
tivemolecular content (cargo) to recipient cells, triggering a variety of biologic responses. Here,wedemonstrated
thatMVs shed fromosteoblasts contain RANKL protein and can transfer it to osteoclast precursors through recep-
tor ligand (RANKL–RANK), leading to stimulation of RANKL–RANK signaling to facilitate osteoclast formation.
Such MV-mediated intercellular communication between osteoblasts and osteoclasts may represent a novel
mechanism of bone modeling and remodeling. It may be worthwhile to further explore MVs as tools to modify
the biological responses of bone cells or develop an alternative drug to treat bone diseases.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bone is a metabolically active tissue which undergoes constant re-
modeling that involves resorption of mineralized bone by osteoclasts
and the synthesis of bone matrix by osteoblasts. This bone remodeling
process is tightly controlled and is essential for the correct function
and maintenance of the skeletal system, repairing microscopic skeletal
damage and replacing aged bone, with the key participant being the os-
teoclast [1,2]. Osteoclasts are multinucleated bone resorbing cells
formed by cytoplasmic fusion of their mononuclear precursors which
are derived from hematopoietic stem cells and share precursors with
macrophages. Understanding of the molecular mechanisms that
regulate osteoclast formation and activation has advanced rapidly
since the discovery of the receptor activator of nuclear factor-κB ligand
(RANKL)/RANK system. RANKL, a type II homotrimeric transmembrane
protein, produced by osteoblasts as amembrane-associated factor binds
to RANK, a receptor for RANKL on the surface of osteoclast precursors,
and RANK–RANKL recognition induces the differentiation of the precur-
sors into osteoclasts [1]. In this process, cell-to-cell contact (osteoblasts
to osteoclast precursors) is required for RANKL/RANK signaling.Medicine, QianRong Road #20,
g0301@126.com (Y. Wang),
. This is an open access article underUsually, cells communicate and exchange information is ascribed to
direct cell-to-cell contact (adhesion, juxtacrine interactions) or transfer
by soluble mediators, whichmay also circulate in blood and body ﬂuids
and act in a regional or systemic manner [3]. However, recent studies
have suggested that cells may also communicate by circular membrane
fragments called microvesicles (MVs), which can fuse to nearby cells
within their circulatory pathways [3–6]. Microvesicles are membrane-
bound vesicular particles and released into the extracellular environ-
ment. MVs shed from the cell surface by most cell types can “packet”
membrane components and engulf cytoplasmic contents including re-
ceptor proteins, proteolytic enzymes, signaling molecules, as well as
mRNA andmicroRNA (miR) sequences, then transfer genetic and prote-
omic information to target cells, in turn to affect cell functions [7,8].
Such molecular pathways of cell-to-cell communication may play an
important role in development, health and disease and has gained
more and more attentions.
So far, a growing body of studies has reported that MVs are involved
in cancer cell survival, invasiveness and metastases [9–12]. Tumor-
derived MVs are able to participate in horizontal transfer of bioactive
molecules throughout cancer cell population and to non-transformed
stromal cells, endothelial cells. It has also been reported that MVs
have roles in chronic inﬂammation, atherosclerosis, cardiovascular and
renal diseases [13–16]. In all cases, MVs have been demonstrated to be
important factors leading to the pathophysiology of diseases or indeed
as therapeutic vehicles in possible new treatments. However, the role
of MVs in the communication between bone cells was rarely reported.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bone regulatory proteins and can stimulate osteoclast formation,
whichmay represent a novelmechanism for cell-to-cell communication
in the bone.
Materials and methods
Isolation of MVs from osteoblastic cell culture
The stromal/osteoblastic cell line UAMS-32P (a kind gift from
CA.O'Brien) [17] was used for MVs production. Cells, cultured in α-
minimum essential medium (α-MEM) containing 10% fetal bovine
serum, were treated with or without PTH (0.1 μmol/L) for 12 h. Culture
mediums from about 4 × 107 cells were harvested andwere centrifuged
at 300 ×g for 10 min and 2000 ×g for 10 min to remove cells and large
debris, respectively. Supernatants were further centrifuged at 16000 ×g
at 4 °C for 60min. The pelletedMVswerewashed in 15mL cold PBS and
centrifuged at 16000 ×g for another 60min, thenMVswere resuspend-
ed in PBS or serum-freeα-MEM. The amount of collectedMVs was esti-
mated by ﬂow cytometric analysis or by measuring MV-associated
proteins, using Pierce® BCA Protein Assay Kit.
Flow cytometry analysis
Labeling of MVs was performed by adding 1 μL of RANKL antibody
(100 μg/mL, Santa Cruz) to 100 μL MVs suspension and incubated at
4 °C for 2 h. Supernatants were discarded after centrifugation at
16000 ×g at 4 °C for 60 min. Then, 1 μL of the FITC-labeled anti-goat
IgG (400 μg/mL, Santa Cruz) was added to 100 μL MVs suspension and
incubated at 4 °C for 1 h. After centrifugation, the supernatants were
discarded and labeled MVs suspension was diluted to 1 mL with PBS,
and ﬂuorescence was analyzed by ﬂow cytometry (BD FACSCalibur).
Western blot analysis
MVs released from about 4 × 107 UAMS-32P cells were lysed with
RIPA buffer supplemented with a protease inhibitor mixture (Roche).
Samples were then subjected to 10% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and electroblotted onto PVDF
membranes (Life Technologies, Grand Island, NY, USA). Themembranes
were incubated with a primary antibody, followed by incubation with
HRP-conjugated secondary antibody. Immunoreactive bandswere visu-
alizedwith ECLwestern blotting luminol reagent (Santa Cruz). Densito-
metric analysis was performed using Image J software. Antibodies
speciﬁc for RANKL, ﬂotillin-2 andβ-actinwere from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA).
Transmission electron microscopy
Sample preparation, thin sectioning, and immunolabeling on section
were performed essentially as described previously [18] with antibody
against RANKL at 50 μg/mL and gold-coupled secondary antibody at
0.65 μg/mL. Sections were poststained with aqueous uranyl acetate/
lead citrate and then examined with Hitachi HT7700 transmission elec-
tron microscopy.
Osteoclast formation assay
MVs released from about 4 × 107 UAMS-32P cells were suspended in
100 μL serum-free α-MEM medium, and 10 μL of MVs was co-cultured
with RAW264.7 cells (3 × 105 cells/well) in 24-well plate (1 mL/well)
for 6 days in α-MEM complete medium. On day 3, the mediumwas re-
placed with freshmedium and supplemented with 10 μL of MVs. At the
endof the culture period, the cellswereﬁxed in 10% formalin for 10min,
permeabilized with 0.1% Triton X-100 in PBS, and then stained fortartrate-resistant acid phosphatase (TRAP) by using the TRACP& ALP
double-stain Kit (TaKaRa).
Generation of GFP-tagged stromal/osteoblastic cell line and ﬂuorescence la-
beled MVs
Plasmid harboring retroviral vector pCAG-Mem-GFP (a kind gift
from prof. Quansheng Zhou of the Soochow University), which
expressed fusion protein of 20 N-terminal amino acids of neuromodulin
and green ﬂuorescent protein (GFP), was co-transfected with pCL-
AmphoRetrovirus Packaging Vector into HEK293T cells using Lipofecta-
mine 2000 (Invitrogen). Supernatants containing viral particles were
collected between 48 and 72 h, ﬁltered (0.22 μm) and then stored at
−80 °C. UAMS-32P cells were infected with viral supernatants in the
presence of 8 μg/mL Polybrene (Santa Cruz, CA, USA) for 72 h. The
GFP-positive cells were sorted by ﬂow cytometry.
Pelleted MVs released from GFP-tagged UAMS-32P cells with or
without PTH treatment were performed in cold PBS, and total ﬂuores-
cence was assayed at 488/597 nm with a spectrophotometric system
(SpectraMax M5e, Molecular Devices, USA).
Fluorescence confocal microscopy
MVs released from about 4 × 107 GFP-tagged UAMS-32P cells were
suspended in 100 μL cold PBS and 20 μL of MVs was co-cultured with
target cells in 35 mm plates which were glass bottom. The time-lapse
images for interaction between MVs and living cells were acquired
with a confocal laser-scanning microscopy (Zeiss LSM 510) ﬁtted with
a ×40 objective.
Results
Osteoblast-derived MVs contain RANKL protein
A previous study has reported that parathyroid hormone (PTH) can
stimulate RANKL up-regulation in primary cultures of stromal/osteo-
blastic cells [19]. Although MVs have been reported to contain numer-
ous proteins and lipids similar to those present in the membranes of
the cells fromwhich they originate [7,8], we were interested in observ-
ing whether MVs shed from UAMS-32P cells upon PTH triggering con-
tain RANKL protein. Thus, we ﬁrst performed western blot analysis
using RANKL antibody to detect the existence of RANKL protein in the
MVs released from UAMS-32P cells. As shown in Fig. 1A, RANKL in-
creased signiﬁcantly in MVs shed from PTH-treated cells, whereas the
amount of the MV marker ﬂotillin-2 [20] was nearly equivalent. Flow
cytometry analysis further conﬁrmed RANKL protein present in MVs
shed from UAMS-32P cells (Fig. 1B). Additionally, visual results by
immunoelectron microscopy also indicated the presence of RANKL on
the surface of MVs from UAMS-32P cells (Fig. 1C).
The number of MVs present in the culture supernatants was quanti-
ﬁed by ﬂow cytometry. The amount of MVs released with PTH treat-
ment was higher than without treatment (71167 ± 1465 vesicles/min
vs 33417 ± 382 vesicles/min, obtained from 4 × 107 cells, Fig. 1D). Be-
sides, it is also accompanied by a corresponding increase in the total
amount of protein of MVs released from the cells with PTH treatment
(168.22 ± 1.44 μg vs 62.55 ± 1.25 μg, obtained from 4 × 107 cells,
Fig. 1E). These results revealed that MVs shed from osteoblasts
contained osteoblastmembrane proteins and PTHpromoted the release
of MVs from osteoblasts.
Osteoblast-derived MVs stimulate osteoclast formation
MVs are able to transfer various components of their contents into
the membranes of target cells, triggering a variety of biologic activity.
To examinewhether osteoblast-derivedMVs could transfer RANKL pro-
tein to osteoclast precursors and stimulate osteoclast formation, MVs
Fig. 1. Biochemical characterization of theMVs shed from UAMS-32P cells. (A) Lysates ofMVs from UAMS-32P cells with or without PTH treatmentwere prepared and subjected towest-
ern blot analysis for RANKL, ﬂotillin-2 and β-actin (30 μg/lane). (B) FITC-labeled RANKL on surface of MVs shed from UAMS-32P cells with or without PTH treatment was determined by
FACSanalysis. (C) Ultrastructural localization of RANKL (arrows) onMVs shed fromUAMS-32P cellswith orwithout PTH treatment. Bar: 200nm. (D) The amount ofMVs shed fromUAMS-
32P cellswith orwithout PTH treatmentwas quantiﬁed byﬂow cytometry (obtained from4×107 cells). (E) The total amount of protein ofMVs shed fromUAMS-32P cellswith orwithout
PTH treatment (obtained from 4 × 107 cells). Each bar represents the mean ± STDEV (n = 3). *, P b 0.05 by Student's t test. Vehicle: without PTH treatment; PTH: with PTH treatment.
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cultured with RAW264.7 cells, the macrophage cell line which can dif-
ferentiate to osteoclast after RANKL stimulation. TRAP staining showed
that MVs prepared from UAMS-32P cells with PTH treatment signiﬁ-
cantly facilitated osteoclast precursor differentiation, and this effect of
MVs could be blocked by adding RANKL antibody or osteoprotegerin
(OPG), which is a soluble decoy receptor for RANKL that blocks ligand
binding to RANK, thereby preventing the signaling required for osteo-
clast differentiation and activation (Fig. 2). To further demonstrate
that MVs stimulate RANKL–RANK signaling, we investigated the trans-
location of nuclear factor of activated T cell (NFATc1), which is themas-
ter regulator of osteoclastogenesis in response to RANKL. Results
showed that MVs released from PTH-treated UAMS-32P cells activated
NFATc1 nuclear translocation (Supplemental Fig. 1). These resultsindicated thatMV-mediated transfer of RANKL protein from osteoblasts
to osteoclast precursors was indeed capable of inducing osteoclast
formation. Therefore, the osteoblast-MV delivery system, which affords
fusion of MVs to the plasma membrane of osteoclasts, is a reasonable
transfer model for RANKL.
Fluorescence labeling of MVs
Fluorescent proteins fusedwithMVmembrane protein can be useful
MV tracers. For direct visualization of transfer of MVs from cell to cell in
live culture, we generated GFP-tagged UAMS-32P cells which stably ex-
press green ﬂuorescent protein (GFP) in plasma membrane using a
lentivector system (Fig. 3A). As shown in Fig. 3B, the majority of cells
were positive (97.3% for GFP-tagged). As green ﬂuorescent protein
Fig. 2.Osteoblast-derivedMVs stimulate osteoclast formation. (A) RAW264.7 cells andMVs shed from UAMS-32P cells without PTH treatment (Vehicle group) or with (PTH group)were
co-cultured. OPG (100 ng/mL) and RANKL antibody (100 μg/mL) were preincubated with MVs for 30min to block the effect of MVs (PTH+OPG, PTH+ RANKL antibody group). Soluble
RANKL (10 ng/mL)was added as positive control (RANKL group). Cells were ﬁxed and stained for ALP activity (200×magniﬁcation). (B) The numbers of TRAP staining positive cells. Each
bar represents the mean ± STDEV in 24 well-plate (n = 3). *, P b 0.05 by one-way ANOVA.
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when directly budded from the cell plasma membrane. As shown in
Fig. 3C, ﬂuorescence of MVs, collected from GFP-tagged UAMS-32P
cells with or without PTH treatment, was quantiﬁed by spectrophoto-
metric analysis. Results showed that MVs from GFP-tagged UAMS-32P
cells with PTH treatment had stronger ﬂuorescence, indicating that
PTH facilitated MVs release from osteoblasts.
MVs interact with target cells through speciﬁc receptor ligands
In order to investigate intercellular location of RANKL delivered to
target cells via MVs, we directly visualize the transfer by imaging GFP-
tagged MVs with confocal laser scanning microscopy. As shown in
Fig. 4, GFP-tagged MVs shed from PTH-treated UAMS-32P cells
(RANKL on surface) were bound to the surface of RAW264.7 cells
(RANK on surface) after co-cultured from 4 to 72 h (Fig. 4A). They
were also bound to the surface of RANK-expressing NIH3T3 cells,
whereas they were transferred into cytosol of NIH3T3 cells because of
receptor ligand absence (Fig. 4B). Additionally, preincubated with
RANKL antibody or OPG, MVs were also transferred into cytosol afterco-cultured with RAW264.7 cells (Fig. 4C, D). These results implicate
that MVs interact only with target cells that they speciﬁcally recognize
rather than just with any cell present in the microenvironment.Discussion
Themaintenance of bone homeostasis is largely dependent on cellu-
lar communication between osteoblasts and osteoclasts. Usually, there
are three modes of osteoblast–osteoclast communication. Osteoblasts
and osteoclasts can make direct contact, allowing membrane-bound li-
gands and receptors to interact and initiate intracellular signaling. They
can also form gap junctions allowing passage of small water-soluble
molecules between the two cell types. Communication can also occur
through diffusible paracrine factors, such as growth factors, cytokines,
chemokines and other small molecules secreted by either cell type
and acting on the other via diffusion [21]. Here, we found that
microvesicles, the membrane-bound vesicular particles, released from
osteoblasts can facilitate osteoclast formation, which may represent a
novel mechanism for osteoblasts and osteoclasts communication.
Fig. 3. Identiﬁcation of GFP-tagged UAMS-32P cells and ﬂuorescence labeledMVs. (A) The image of GFP-tagged UAMS-32P cells acquired by ﬂuorescencemicroscope. (B) FACS analysis of
GFP-tagged UAMS-32P cells. (C) Spectrophotometric analysis of ﬂuorescent MVs released from GFP-tagged UAMS-32P cells without (vehicle group) or with PTH treatment (PTH group).
Each bar represents the mean ± STDEV in 6 well-plate (n = 3). *, P b 0.05 by Student's t test.
Fig. 4. Intracellular localization ofMVs in target cells. (A) MVs released from UAMS-32P cells with PTH treatment were bound to the surface of RAW264.7 cells at different times (4, 24,48,
72 h). (B) MVs released from UAMS-32P cells with PTH treatment were transferred into cytosol of NIH3T3 cells or bound to the surface of RANK-expressing NIH3T3 cells (NIH3T3RANK
cells) after incubation for 4 h. (C) MVs pre-incubated with RANKL antibody (100 ng/mL) for 15 min were transferred into cytosol after co-cultured with RAW264.7 cells for 4 h.
(D) MVs pre-incubated with OPG (100 ng/mL) for 15 min were transferred into cytosol after co-cultured with RAW264.7 cells for 4 h.
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membrane into the extracellular environment. They contain numerous
proteins and lipids similar to those present in the membranes of the
cells fromwhich they originate and are able to transfer various com-
ponents of their contents into themembranes of target cells, trigger-
ing a variety of biologic responses. In this study, we conﬁrmed that
osteoblast-derived MVs contain RANKL, a member of the tumor
necrosis factor (TNF) family of cytokines, produced by stromal/
osteoblasts as a membrane-bound protein; when MVs co-cultured
with osteoclast precursors, they interacted with target cells and
stimulated the osteoclast precursor differentiation to osteoclasts
with osteoblasts absent.
There are different mechanisms by which MVs may interact with
target cells. MVs may act as signaling complexes by direct stimulation
of target cells; may act by transferring surface receptors between cells;
may deliver proteins, mRNA and bioactive lipids into the target cells;
and may deliver infectious agents into cells. In the present study, we
found that osteoblast-derived MVs interacted with target cells
(RAW264.7 cells; osteoclast precursors) that speciﬁcally recognized
through receptor ligand (RANKL–RANK); other cellswithout speciﬁc re-
ceptor were not recognized. This interaction was also limited to a
receptor-mediated binding to the surface of target cells leading to cell
signaling. OPG addition blocked MV-derived RANKL binding to RANK,
resulting in the prevention of the signaling required for osteoclast dif-
ferentiation. This observation implicated that MVs released from a
given cell type may interact through speciﬁc receptor ligands with
other cells, leading to target cell stimulation by transferring surface
receptors.
An interesting and important ﬁnding was that MVs were internal-
ized when the speciﬁc recognition could not be achieved between
osteoblast-derivedMVs and target cells. Once internalized,MVsmay re-
main segregated and be transferred to lysosomes or dismissed by the
cells following the fusion with the plasma membrane, thus leading to
a process of transcytosis; the detail studies on this should be performed
in the future. Besides, this study was focused on RANKL pathway on
osteoblast-derived MVs, whether other marker proteins such as E11,
sclerostin, and FGF23 will present in the MVs and how they affect
osteoclast formation should be explored in future studies. Furthermore,
efﬁcient strategies that will allow us to modulate MVs secretion should
be developed, thus we can employMVs as tools tomodify the biological
responses of bone cells or develop an alternative drug to treat bone
diseases.
Collectively, RANKL-containing MVs released from osteoblasts were
transferred to osteoclast precursors, which resulted in the stimulation
of RANKL–RANK signaling to facilitate osteoclast formation. Such
MV-mediated intercellular communication between osteoblasts
and osteoclasts may represent a novel mechanism of bone modeling
and remodeling.
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